Cagrilintide

What Cagrilintide does

Cagrilintide copies the fullness hormone amylin. Human trials studied it alone and with semaglutide. It reduced weight, but it has no approved dosing label as of October 18, 2026. Nausea, bowel symptoms and injection-site reactions are common; long-term safety and online-vial quality remain uncertain.

• In a large trial, all five weekly doses tested led to more weight loss than placebo. (Studied in a trial)
• In trials, adding it to semaglutide led to more weight loss than semaglutide alone. (Studied in a trial)
• In a small diabetes trial, blood sugar improved, but this is less proven than its use with semaglutide. (Studied in a trial)
• Some people report less hunger, even at small doses; others report no effect. (Reported by users)

Uses in the sources

• Studied alone for weight loss in adults with obesity or overweight with related health conditions. (Studied in a trial) (source)
• A small diabetes trial found glucose improvement; standalone diabetes benefit is less established than combination benefit. (Studied in a trial) (source)

Cagrilintide dosage

Typical reported dose: 0.25 mg once a week to start, up to 2.4 mg

• Phase 2: 0.3 mg: 0.3 mg once weekly once weekly, under the skin. Studied in a trial. Studied in: Adults with obesity or overweight with hypertension/dyslipidemia; no diabetes. (source)
• Phase 2: 0.6 mg: 0.6 mg once weekly once weekly, under the skin. Studied in a trial. Studied in: Adults with obesity or overweight with hypertension/dyslipidemia; no diabetes. (source)
• Phase 2: 1.2 mg: 0.6 mg once weekly, then 1.2 mg once weekly once weekly, under the skin. Studied in a trial. Studied in: Adults with obesity or overweight with hypertension/dyslipidemia; no diabetes. (source)
• Phase 2: 2.4 mg: 0.6 mg once weekly, then 1.2 mg once weekly, then 2.4 mg once weekly once weekly, under the skin. Studied in a trial. Studied in: Adults with obesity or overweight with hypertension/dyslipidemia; no diabetes. (source)
• Phase 2: 4.5 mg: 0.6 mg once weekly, then 1.2 mg once weekly, then 2.4 mg once weekly, then 4.5 mg once weekly once weekly, under the skin. Studied in a trial. Studied in: Adults with obesity or overweight with hypertension/dyslipidemia; no diabetes. (source)
• Diabetes trial: 2.4 mg: 0.25 mg once weekly, then 0.5 mg once weekly, then 1 mg once weekly, then 1.7 mg once weekly once weekly, under the skin. Studied in a trial. Studied in: Adults with type 2 diabetes and BMI ≥27 on metformin, with or without an SGLT2 inhibitor. (source)

Highest studied: Highest verified published SC weekly cagrilintide target: 4.5 mg..

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

How to mix Cagrilintide

Comes as: Trial injection solutions in controlled devices., Community-reported freeze-dried vials; no approved home-use product..

Mixed with: Community reports use bacteriostatic water; compatibility and shelf life are not established..

Common vial sizes: 5, 10 mg. Common water amounts: 1, 2 mL.

• Community examples: 5 mg with 1 mL, or 10 mg with 2 mL. These describe reports, not validated handling.
• Do not transfer storage instructions from an approved semaglutide pen to cagrilintide powder.
• No verified at-home acid-adjustment method or beyond-use date was located.

Before mixing: No validated storage temperature or shelf life for community powder vials was found.

After mixing: No validated home-mix stability or sterility period was found. Refrigeration does not prove either.

Cagrilintide side effects and risks

Reported side effects

• Nausea: 20–47% across phase 2 doses versus 18% placebo., moderate. Persistent symptoms call for review before any increase. (source)
• Injection-site reactions: 16.9% at 2.4 mg alone versus 3.0% placebo in REDEFINE 1., mild (source)
• Gallbladder disorders: 2.3% at 2.4 mg alone versus 1.0% placebo in REDEFINE 1., serious (source)
• Fatigue and marked appetite loss: Reported online; reliable cagrilintide specific rates are unavailable., moderate (source)
• Serious allergic reaction: Risk is plausible; a reliable monotherapy anaphylaxis rate is unavailable., serious (source)
• Low blood sugar with insulin: Class based concern; 92 person diabetes trial reported no level 2/3 episodes., serious (source)
• Constipation: At 2.4 mg: 17/102 versus 7/101 placebo in the phase 2 registry., moderate (source)
• Diarrhea: At 2.4 mg: 18/102 versus 9/101 placebo in the phase 2 registry., moderate (source)
• Vomiting: At 2.4 mg: 9/102 versus 3/101 placebo in the phase 2 registry., moderate (source)

Stop and get help if

• Severe or persistent belly pain, especially with vomiting: Stop and seek urgent assessment for pancreatitis, gallbladder disease or obstruction.
• Throat swelling, breathing trouble or collapse: Stop and call emergency services for possible anaphylaxis.
• Confusion, fainting or low sugar that does not recover: Seek emergency care; do not give food or drink to an unconscious person.
• Cannot keep fluids down, very little urine or marked dizziness: Seek urgent care for dehydration or kidney injury.
• Persistent squeezing chest pain, or chest pain with breathlessness: Call emergency services.
• Sudden vision loss or a new major vision change: Get emergency care for sudden loss of sight; urgent assessment for other new changes.

Who should avoid it

• pregnant: Pregnancy was excluded; weight-loss use and fetal safety are not established.
• breastfeeding: Breastfeeding was excluded; infant exposure and safety are unknown.
• tryingToConceive: Conception attempts were excluded. A cagrilintide-specific washout is not established.
• under18: Adult results do not establish youth safety; pediatric trials are ongoing.
• eatingDisorderHistory: Precaution: appetite suppression can worsen restrictive eating or poor nutrition.
• gastroparesis: Amylin-class concern: delayed stomach emptying may worsen symptoms; cagrilintide-specific limits are unknown.
• diabetes: Review insulin, low-sugar risk and food intake before adding an appetite suppressant.
• kidneyDisease: Single-dose PK was reassuring; dehydration and repeated-dose safety still need review.
• liverDisease: Single-dose liver PK did not change meaningfully; chronic severe-disease safety remains uncertain.
• pancreatitisHistory: Review the history before use; monotherapy evidence in this group is limited.
• gallbladderDisease: Gallbladder events occurred in 2.3% of monotherapy users versus 1.0% placebo in REDEFINE 1.
• heartCondition: The QT study was reassuring but did not assess every heart risk.
• surgeryPlanned: Tell the anesthesia team about use; amylin-related stomach-emptying effects may matter.
• testedAthlete: Apply WADA S0 to an unapproved drug; obtain a current sport-specific ruling.
• other: A serious allergic reaction to the compound or an ingredient should stop further exposure.

Interactions

• Insulin and sulfonylureas: Amylin-class concern: less food and insulin exposure can cause low blood sugar; cagrilintide-specific risk is uncertain.
• Oral medicines with narrow dosing margins: Stomach-emptying effects may alter timing of absorption. Review drug levels or INR; a cagrilintide effect is not proven.
• Oral contraception: An interaction study exists but no results were found. Do not import tirzepatide’s four-week rule as cagrilintide evidence.
• Other amylin drugs: Avoid duplicate amylin exposure; the combination has no established safety schedule.
• GLP-1 and related weight-loss drugs: Semaglutide pairing has trial evidence. Tirzepatide and retatrutide stacks lack verified human combination evidence.

Product quality risks

• No independent cagrilintide retail-vial testing study was found.
• An online semaglutide study found 7.7–14.37% purity and endotoxin; those findings cannot be assigned as cagrilintide rates.
• Unapproved vials may have wrong identity, wrong dose, impurities or contamination.

What to expect

• Weeks 1-2, phase 2 higher-dose paths: The 1.2 mg, 2.4 mg and 4.5 mg target groups began at 0.6 mg weekly in the phase 2 trial.
• Weeks 3-4, phase 2 higher-dose paths: Those phase 2 groups moved to 1.2 mg weekly after two weeks.
• Weeks 5-6, phase 2 higher-dose paths: The phase 2 groups targeting 2.4 mg or 4.5 mg moved to 2.4 mg weekly.
• Week 7 onward, phase 2 highest-dose path: The phase 2 group targeting 4.5 mg reached that weekly dose after six weeks.
• Week 26: The phase 2 trial estimated 6.0-10.8% average weight loss if treatment was followed versus 3.0% with placebo, with nausea common.

The phase 2 obesity trial used weekly injections for 26 weeks, then six weeks of follow-up without treatment.

27 unique registered studies with cagrilintide-alone or comparator arms; includes ongoing/unreported trials. Reviews and animal studies are not counted.

Key studies

• First human single-dose study: Status: completed. No clinical benefit is established by registration. (source)
• First repeat-dose study: Status: completed. No clinical benefit is established by registration. (source)
• Japanese and White adults: PK: Status: completed. No clinical benefit is established by registration. (source)
• Phase 2: five weekly doses: All five cagrilintide doses reduced weight more than placebo. (source)
• Birth-control pill interaction: Status: completed. No clinical benefit is established by registration. (source)
• Single dose: kidney impairment: A single dose showed no clinically relevant kidney-related exposure change. (source)

Cagrilintide FAQ

• Is Cagrilintide FDA-approved? No FDA-approved cagrilintide product or label found.
• How do people take it? Under the skin, once weekly. 68 weeks. Source: studied in a trial.
• What's the difference between Cagrilintide and Semaglutide? Cagrilintide: an unapproved weekly amylin analogue with weight-loss trials and common stomach symptoms. Semaglutide: a GLP-1 medicine with strong weight, glucose, heart and kidney evidence; dose and formulation matter. Why people pair them: adds GLP-1 activity; CagriSema is the studied combination.
• Can I take it with Semaglutide? Adds GLP-1 activity; CagriSema is the studied combination. More stomach symptoms and combined appetite suppression; home mixing was not tested. Source: studied in a trial. Ask a doctor before combining anything.
• Is it banned in sport? Yes. It is banned in and out of competition (WADA 2026). Application of the S0 rule to unapproved cagrilintide; not an individual named listing. Confirm with the athlete’s anti-doping body.
• How long does a mixed vial last? No validated home-mix stability or sterility period was found. Refrigeration does not prove either.